HUTCHMED (NASDAQ:HCM) Shares Gap Down – Time to Sell?

Shares of HUTCHMED (China) Limited (NASDAQ:HCM) gapped down before the market opened on Friday . The stock had previously closed at $13.97, but opened at $13.42. HUTCHMED shares last traded at $13.26, with a volume of 42,252 shares changing hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut HUTCHMED from a “buy” rating to a “hold” rating in a research note on Monday, November 18th.

HUTCHMED Price Performance

The stock has a 50 day moving average price of $14.85 and a two-hundred day moving average price of $17.24. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in HCM. Public Employees Retirement System of Ohio bought a new position in shares of HUTCHMED during the 3rd quarter worth approximately $35,000. Blue Trust Inc. raised its position in HUTCHMED by 638.2% in the 3rd quarter. Blue Trust Inc. now owns 3,536 shares of the company’s stock valued at $69,000 after purchasing an additional 3,057 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of HUTCHMED by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company’s stock valued at $117,000 after buying an additional 2,321 shares during the period. Summit Trail Advisors LLC increased its stake in shares of HUTCHMED by 14.4% in the 4th quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company’s stock valued at $189,000 after buying an additional 1,647 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of HUTCHMED during the second quarter worth $213,000. Institutional investors and hedge funds own 8.82% of the company’s stock.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.